Table 1.

List of currently approved antibody–drug conjugates for the treatment of solid malignancies

	Target	Indication	Payload	Mechanism of action	DAR	Linker	Payload t1/2	Cycle dose
Trastuzumab emtansine	HER2	Breast cancer	DM1 emtansine	Tubulin inhibitor	3.5	Non-cleavable	NA	3.6 mg/kg
Trastuzumab deruxtecan	HER2	Breast, gastric, non-small-cell lung cancer	Exatecan derivative	Topoisomerase inhibitor	8	Cleavable	5.8 days	5.4 mg/kg
Sacituzumab govitecan	TROP2	Breast, urothelial cancer	SN38	Topoisomerase inhibitor	7.6	Cleavable	0.75 days	20 mg/kg
Enfortumab vedotin	Nectin-4	Urothelial cancer	MMAE	Tubulin inhibitor	4	Cleavable	2.4 days	3.75 mg/kg
Tisotumab vedotin	Tissue factor	Cervical cancer	MMAE	Tubulin inhibitor	4	Cleavable	NA	2 mg/kg
Mirvetuximab soravtansine	Folate receptor alpha	Ovarian cancer	DM4	Tubulin inhibitor	3.4	Cleavable	NA	6 mg/kg

DAR, drug-to-antibody ratio; DM1/DM4, maytansinoids; HER2, human epidermal growth factor receptor 2; MMAE, Monomethyl auristatin E; NA, not available; t_1/2, half-life; TROP2, trophoblast cell surface antigen 2.